Beijing Excellence Future International Consulting

Excellence Future is a prominent Chinese Contract Research Organization (CRO) that provides comprehensive clinical research services to the pharmaceutical and medical device industries. Established in 2002, the company specializes in clinical trial management (Phase I-IV), regulatory affairs, medical writing, and data management. In 2019, the company was acquired by Hangzhou Tigermed Consulting, a leading global CRO, to enhance its clinical trial execution capabilities within the Chinese market. Excellence Future is known for its deep expertise in NMPA regulatory compliance and its extensive network of clinical trial sites across China. The firm supports both domestic and international clients in navigating the complex landscape of drug and device registration in China. Following its acquisition, it operates as a key subsidiary within the Tigermed group, focusing on high-quality clinical operations.